ArticleAngewandte Chemie (International ed. in English)2026
Site-Selective Ligand Selection by Mutational Profiling for Covalent RNA Targeting.
Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- SOLiD-MaP: A Photoproximity Labeling Platform for Small Molecule Binding Site Mapping on RNA.Angewandte Chemie (International ed. in English) · 2026Article
- Mechanistically Defined Epoxide- and Aziridine-2-carboxamide Electrophiles Enable Stereoselective Covalent Ribonucleic Acid Modulation.Journal of the American Chemical Society · 2026Article
- Comparative analysis of alkyne- and desthiobiotinylated photoaffinity probes for chemotranscriptomic profiling.RSC chemical biology · 2026Article
- RNA functional modulation by Mitoxantrone via RNA structural ensemble repartitioning.Nature communications · 2026Article
- Site-Selective Ligand Selection by Mutational Profiling for Covalent RNA Targeting.Angewandte Chemie (International ed. in English) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
To facilitate the design of RNA-targeted covalent probes we report a bottom-up, structure-informed approach using mutational profiling. We designed a compact library of covalent probes based on the scaffold of Ribocil, a selective inhibitor targeting the bacterial FMN riboswitch and screened them against the FMN riboswitch aptamer from Fusobacterium nucleatum, Bacillus subtilis, Escherichia coli, and Staphylococcus aureus. This yielded Covacil, a highly base-selective probe that covalently modifies the FMN riboswitch aptamer at low micromolar concentrations, within 10 minutes. We validate the site-selectivity and covalency of the probe by competitive photo-affinity labelling and mass-spectrometry. When compared to non-targeted covalent probes, Covacil displayed >1,000-fold increased selectivity toward a specific base within the FMN riboswitch aptamer. Finally, we apply Covacil to total RNA and demonstrate that it maintains its base-selective reactivity for the FMN riboswitch within the entire transcriptome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.